The test is conducted by inflating a cuff around the arm for two minutes followed by immediate deflation.
The company's FDA approval follows multiple clinical trials conducted in major cities and supported by a $1 million award from the Texas Emerging Technology Fund, an initiative from Governor Rick Perry's economic reform committee. “Beyond Blood PressureTM” represents an exciting new paradigm for screening, diagnosis, prediction of future risk, tailored therapy and monitoring of cardiovascular disease.
"I am impressed by the data from the Endothelix clinical trials," says Dr. Mathew B
udoff, Professor of Medicine at UCLA and Director of Cardiovascular Imaging at the Los Angeles Biomed Institute. "VENDYS technology is indeed very promising."
Endothelix is a medical company based in Houston, Texas. The company is positioned as the first to incorporate non-invasive, non- imaging micro and macro vascular (endothelial dependent and independent) function monitoring technologies into the existing risk factor assessment to help physicians more accurately monitor their patients cardiovascular health, and to use appropriate therapies for the prevention and treatment heart attack and stroke.
0 comments :
Post a Comment